FDA Greenlights Dogwood's SP16 for Chemotherapy Pain, NCI to Fund Phase 1b Trial
summarizeSummary
Dogwood Therapeutics announced FDA acceptance of its Investigational New Drug (IND) application for SP16, a drug candidate targeting chemotherapy-induced pain and neuropathy. This critical regulatory milestone allows the company to proceed with a Phase 1b clinical trial, with patient enrollment anticipated to begin in mid-2026. This development is particularly significant for Dogwood, a small-cap, development-stage biotech whose auditor recently expressed substantial doubt about its ability to continue as a going concern. The Phase 1b trial for SP16 is fully funded by a $2.5 million grant from the National Cancer Institute to its partner, Serpin Pharma, which materially reduces Dogwood's financial burden and conserves its limited capital. This news provides a much-needed positive catalyst, expanding the company's pipeline and offering a new potential value driver. Investors will now watch for the commencement of patient enrollment and future trial results.
At the time of this announcement, DWTX was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $1.77 to $9.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.